Syphilis is a bacterial sexually transmitted infection (STI) caused by Treponema pallidum, which can lead to severe health complications if left untreated. The disease progresses through multiple stages and can result in neurological, cardiovascular, and congenital conditions.
With the global rise in sexually transmitted infections, syphilis has re-emerged as a major public health concern. Early detection and timely treatment are critical to preventing transmission and long-term complications, particularly congenital syphilis in newborns.
According to BIS Research, the global syphilis market was valued at $718.0 million in 2024 and is projected to reach $1,220.8 million by 2036, growing at a CAGR of 4.60% during 2026–2036. This growth reflects increasing awareness, improved diagnostic capabilities, and expanding screening programs worldwide.
Download the complete TOC and Request Sample Report
• Increasing global incidence of syphilis, particularly among high-risk populations
• Growing awareness regarding early diagnosis and treatment of STIs
• Expansion of public health screening programs, including prenatal testing
• Advancements in rapid diagnostic technologies and laboratory assays
• Rising investments in infectious disease management and sexual health initiatives
• Recurring shortages of Benzathine Penicillin G, the first-line treatment
• Supply chain constraints and limited manufacturing incentives
• Stigma and limited healthcare access in certain regions
• Dependence on injectable treatment methods requiring clinical settings
• Variability in global screening and prevention program effectiveness
• February 2026: Aurobindo Pharma Limited announced plans to scale Penicillin-G production to ~10,000 metric tonnes annually.
• January 2026: India implemented a one-year minimum import price on penicillin derivatives to protect domestic manufacturers.
• March 2025: Sandoz Group AG launched a €50 million antibiotic production facility in Austria, increasing output capacity by ~20%.
• Injectables
• Oral Medications
• Penicillin-based Treatment
• Other Antibiotics
• North America
• Europe
• Asia-Pacific
• Rest-of-the-World
According to Principal Analyst at BIS Research: “The syphilis market is expected to experience sustained growth, supported by rising disease prevalence, improved diagnostic access, and strong public health initiatives. Penicillin-based therapies will remain central to treatment, while innovations in rapid and accessible testing will significantly enhance early detection and disease management. Continued global focus on prevention, particularly in maternal health, will be critical in shaping the future of this market.”
The market is projected to grow at a CAGR of 4.60% from 2026 to 2036, reaching $1,220.8 million by 2036.
Key players include Pfizer Inc., Sandoz Group AG, Teva Pharmaceuticals, Cipla, Fresenius Kabi AG, Eurofarma, AdvaCare Pharma, and Aurobindo Pharma Limited.
Penicillin-based injectable treatments dominate due to their high efficacy and global clinical recommendations.
BIS Research provides expert-driven insights, granular segmentation, and strategic advisory across healthcare, pharmaceuticals, and life sciences domains.
